The invention relates to a pharmaceutical composition comprising an apolipoprotein
construct, to an apolipoprotein construct, a nucleic acid sequence encoding the
apolipoprotein construct, a vector comprising the nucleic acid sequence, a method
for producing the apolipoprotein construct, and a method of treatment comprising
administering the apolipoprotein construct. The presented data document that the
constructs according to the invention are capable of binding lipids, are capable
of binding cubilin, which is a strong Apo AI receptor, stronger than native Apo
A-I and that the plasma half life of the constructs is at least tripled compared
to native Apo A-I. Together these data document that the constructs according to
the invention are strong candidates for treatment of cardiovascular diseases.
